I think this has been the big issue. Trials have been done so far in an age group from the middle group, if you like. There's a top end, where we're not really sure what the dose should be. Yes, these have to be tracked. They've got to be going off with one dose, but they will be doing immunogenicity studies on small subgroups here. This is important not just for Canada; the data will be shared globally. It would be the data from Europe, and that would be shared with us as well.
This is the advantage. It has never happened before on the regulator's side. This is something unusual.